Replies to post #35673 on Relief Therapeutics Holding AG (RLFTF)

[si30]

Wouldn’t have been better to design the trial such that only ZYESAMI was given to patients in one arm and the SOC Remdesivir given to patients in the other arm? This way, if they received the results that they did showing reduced hospitalization in the ZYESAMI arm, that would be a good argument for making ZYESAMI the new SOC.